Climb Bio (CLYM) Common Equity (2020 - 2026)

Climb Bio's Common Equity history runs 7 years deep, the most recent figure standing at $148.1 million for Q1 2026.

• Quarterly Common Equity fell 23.42% year-over-year to $148.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.1 million (down 23.42% YoY) and the FY2025 annual result came in at $160.5 million, down 24.26% from the prior year.
• Common Equity was $148.1 million for Q1 2026 at Climb Bio, down from $160.5 million in the prior quarter.
• Across five years, Common Equity topped out at $222.3 million in Q2 2024 and bottomed at $106.4 million in Q1 2024.
• A 5-year average of $154.8 million and a median of $148.1 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity jumped 459.27% — and 2023, when it retreated 24.68%.
• Climb Bio's Common Equity stood at $128.7 million in 2022, then fell by 16.41% to $107.6 million in 2023, then jumped by 96.92% to $211.9 million in 2024, then dropped by 24.26% to $160.5 million in 2025, then fell by 7.72% to $148.1 million in 2026.
• Business Quant data shows CLYM's Common Equity at $148.1 million in Q1 2026, $160.5 million in Q4 2025, and $177.0 million in Q3 2025.